Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.2010
-0.0071-3.41%
Post-market: 0.2001-0.0009-0.45%19:24 EDT
Volume:4.62M
Turnover:906.67K
Market Cap:21.11M
PE:-0.07
High:0.2116
Open:0.2116
Low:0.1893
Close:0.2081
52wk High:3.39
52wk Low:0.1611
Shares:105.00M
Float Shares:89.28M
Volume Ratio:0.59
T/O Rate:5.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8900
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-209.03%
PB:-0.55
PE(LYR):-0.11

Loading ...

Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026— Baidu, Rubico, Intelligent Bio Solutions In Focus

Benzinga
·
Jan 02

Outlook Therapeutics Shares Plunge 61.5% Premarket After US FDA Declines to Approve Eye Disease Drug

THOMSON REUTERS
·
Jan 02

Stocks to Watch: Nuvve, Outlook Therapeutics, Rubico

Dow Jones
·
Jan 01

BRIEF-Outlook Therapeutics Provides Regulatory Update On U.S. FDA Review Of Lytenava

Reuters
·
Jan 01

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

Dow Jones
·
Jan 01

Outlook Therapeutics Says FDA Issued Complete Response Letter to ONS-5010 BLA Resubmission

MT Newswires Live
·
Jan 01

US FDA declines to approve Outlook Therapeutics' eye disease drug

Reuters
·
Jan 01

Outlook Therapeutics Inc - FDA Issues Complete Response Letter for Ons-5010 Bla

THOMSON REUTERS
·
Jan 01

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™ (Bevacizumab-Vikg) for the Treatment of Wet Amd

THOMSON REUTERS
·
Jan 01

Outlook Therapeutics Inc: Currently Exploring All Available Pathways for Potential Approval in U.s

THOMSON REUTERS
·
Jan 01

Outlook Therapeutics Inc: FDA Has Not Indicated What Type of Confirmatory Evidence Would Be Acceptable

THOMSON REUTERS
·
Jan 01

NASDAQ TRADE HALT HALT NEWS PENDING AT 04:10 PM

Reuters
·
Jan 01

Outlook Therapeutics Grants Stock Options to New Employees

Reuters
·
Dec 27, 2025

BRIEF-Outlook Therapeutics FY EPS USD -1.79

Reuters
·
Dec 19, 2025

Outlook Therapeutics FY2025 net loss narrows to USD 62.4 million, revenue reaches USD 1.4 million

Reuters
·
Dec 19, 2025

Outlook Therapeutics FY Net Income USD -62.4 Million

THOMSON REUTERS
·
Dec 19, 2025

Press Release: Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Dow Jones
·
Dec 19, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 18, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 15, 2025

H.C. Wainwright Sticks to Its Hold Rating for Outlook Therapeutics (OTLK)

TIPRANKS
·
Nov 15, 2025